Preliminary Data On New Valve Platform Shows Benefit
Edwards Lifesciences Corporation, a leader in the science of heart valves and hemodynamic monitoring, recently announced the U.S. and European launches of its Carpentier-Edwards PERIMOUNT Magna Mitral Ease valve, designed to enhance implantation in the mitral position.
The Magna Mitral Ease valve incorporates new features to facilitate access, placement and suturing during both conventional and minimally invasive heart valve surgeries, especially those using a thoracotomy. Its product enhancements, such as the tri-colored holder, suture guide line, saddle-shaped cuff and new accessories are all designed for easier implantation. Magna Mitral Ease is based on the clinically proven and durable Edwards PERIMOUNT mitral valve design, which has more than 250,000 patient years of experience worldwide. Patients with tissue valves such as Magna Mitral Ease can hopefully minimize the need for the lifelong prescription of blood thinners and its associated risks.
Dr. Malakh Shrestha, Hannover Medical School, provided a preliminary, single-center case presentation on Edwards' investigational, minimally invasive, rapid deployment Odyssey aortic valve platform. This initial series of aortic valve replacement (AVR) procedures at Hannover using the Odyssey platform demonstrated an approximately 50 percent reduction in bypass and cross-clamp times when compared to conventional, isolated aortic valve surgery. The Odyssey platform is currently being studied in Europe as part of the TRITON trial, and additional data are expected to be announced after enrollment and patient follow-up is complete.
Dr. Shrestha provides paid consulting services to Edwards Lifesciences for educational programs.